Autoimmune Diseases

Myasthenia Gravis


Publishing date
01 Nov 2011
Status
Published
Submission deadline
01 May 2011

Lead Editor

1Department of Clinical Medicine, University of Bergen, Bergen, Norway

2Division of Neuroimmunology, Department of Neurology, Wayne State University, Detroit, MI 48202, USA

3Neuromuscular Disease Department, National Neurological Institute, C Besta, Milan, Italy


Myasthenia Gravis

Description

Myasthenia gravis (MG) is an autoimmune disorder with the production of antibodies to the n-acetylcholine receptor (AChR) as the best defined autoimmune disturbance. Some MG patients who do not have AChR antibodies (“seronegative”) have antibodies to muscle-specific kinase (MuSK). In addition, some MG patients, especially those who also have a tumour of the thymus gland, have antibodies to other muscle proteins such as titin, ryanodine receptor, and voltage-gated potassium receptor. MG is accompanied with genetic factors that influence the age at onset of neuromuscular symptoms and that differ between patients with and without thymoma. The role of cytokines and CD4+ cells in the pathogenesis of MG remains unclear.

The main focus of this special issue will be on the characterization of the autoimmune responses in MG, the genetic markers that seem to predict the development of the autoimmune disease, and the relationship between the immunological disturbances and the clinical picture. The special issue will summarize the most recent developments in the area. Potential topics include, but are not limited to:

  • B-cell activating factors in different forms of MG
  • Genetic markers in MG
  • Evidence for virus infection of thymus cells in MG
  • Associated inflammatory myositis in MG
  • Immunological diagnosis of thymoma in MG
  • Relationship between the immunological disturbances and the clinical picture

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2011
  • - Article ID 697575
  • - Editorial

Myasthenia Gravis

Johan A. Aarli | Nils Erik Gilhus | ... | Shigeaki Suzuki
  • Special Issue
  • - Volume 2011
  • - Article ID 939520
  • - Review Article

B-Cell-Activating Factor and Autoimmune Myasthenia Gravis

Samia Ragheb | Robert P. Lisak
  • Special Issue
  • - Volume 2011
  • - Article ID 404101
  • - Review Article

Juvenile Myasthenia Gravis: A Paediatric Perspective

Maria F. Finnis | Sandeep Jayawant
  • Special Issue
  • - Volume 2011
  • - Article ID 847393
  • - Review Article

Myasthenia Gravis: A Review of Available Treatment Approaches

Nils Erik Gilhus | Jone F. Owe | ... | Johan A. Aarli
  • Special Issue
  • - Volume 2011
  • - Article ID 973808
  • - Review Article

Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy

Nils Erik Gilhus
  • Special Issue
  • - Volume 2011
  • - Article ID 213092
  • - Research Article

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis

Paola Cavalcante | Lorenzo Maggi | ... | Renato Mantegazza
  • Special Issue
  • - Volume 2011
  • - Article ID 250561
  • - Review Article

Anaesthetic Considerations in Paediatric Myasthenia Gravis

Oliver William Masters | Oliver N. Bagshaw
  • Special Issue
  • - Volume 2011
  • - Article ID 808607
  • - Research Article

Long-Term Respiratory Muscle Endurance Training in Patients with Myasthenia Gravis: First Results after Four Months of Training

Beate Rassler | Grit Marx | ... | Irene Baumann
  • Special Issue
  • - Volume 2011
  • - Article ID 474512
  • - Review Article

Thymoma in Myasthenia Gravis: From Diagnosis to Treatment

Fredrik Romi
  • Special Issue
  • - Volume 2011
  • - Article ID 151258
  • - Clinical Study

Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls

Steven P. Luckman | Nils Erik Gilhus | Fredrik Romi
Autoimmune Diseases
 Journal metrics
Acceptance rate-
Submission to final decision-
Acceptance to publication-
CiteScore3.300
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.